Senior Vice President, Operations — Jeffrey Zerillo: The executive is retiring from a senior operational role, which constitutes an orderly succession rather than a sudden loss or shock departure.

Results of Operations and Financial Condition. On August 6, 2026, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter ended June 30, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter ended June 30, 2026 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Entry into a Material Definitive Agreement. On July 15, 2026, Prestige Brands, Inc. (“Prestige Brands”), a wholly owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), issued $400.0 million aggregate principal amount of 6.250% senior notes due 2034 (the “2026 Notes” or “notes”) pursuant to an Indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as truste…

Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. On July 1, 2026 (the “Closing Date”), Prestige Consumer Healthcare Inc. (the “Company”) and its wholly-owned subsidiary, Prestige Brands, Inc. (the “Borrower”), entered into an amendment (the “Amendment”) to that certain Term Loan Credit Agreement (the “Term Loan Credit Agreement”) by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Cit…

Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant. Also on the Closing Date, the Borrower borrowed $95,000,000 under the Amendment to finance the LaCorium Acquisition, which closed on the Closing Date, together with fees and expenses incurred in connection with the closing of the LaCorium Acquisition.

Entry into a Material Definitive Agreement. New Term Loan Facility On June 12, 2026 (the “Closing Date”), Prestige Consumer Healthcare Inc. (the “Company”) and its wholly-owned subsidiary, Prestige Brands, Inc. (the “Borrower”), entered into that certain Term Loan Credit Agreement (the “Term Loan Credit Agreement”) by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Citibank, N.A…

Completion of Acquisition or Disposition of Assets. On June 12, 2026, the Borrower and Medtech Products Inc. (“MedTech”), a wholly-owned subsidiary of the Company, completed the previously announced acquisition of Breathe Right® and certain other brands (the “Breathe Right Business”) from Foundation Consumer Brands, LLC and certain of its affiliates, pursuant to an Asset Purchase Agreement, dated as of March 19, 2026 (the “Purchase Agreement”), for a purchase price of $1.045 billion in cash (…

Other Events. On June 15, 2026, the Company issued a press release announcing the Company’s entry into the Term Loan Credit Agreement, the ABL Amendment and the completion of the Transaction. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant. The information set forth in

Results of Operations and Financial Condition. On May 13, 2026, the Company announced financial results for the fiscal quarter and year ended March 31, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2026 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Entry into a Material Definitive Agreement. On May 10, 2026, PBH Australia Holding Company Pty Limited (“Purchaser”), an Australian company and a wholly owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), and Care Pharmaceuticals Pty Limited (“Care”), an Australian company and a wholly owned indirect subsidiary of the Company, entered into a definitive agreement (the “Sale and Purchase Deed”) with Tailor Investments Pty Limited and Standive Pty Limited, both Austra…

Entry into a Material Definitive Agreement. On March 19, 2026, Prestige Brands, Inc. (“Purchaser”), a Delaware corporation and a wholly-owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), entered into a definitive agreement (the “Asset Purchase Agreement”) with Foundation Consumer Brands, LLC (“Foundation”), a Delaware limited liability company. The Asset Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire…

Results of Operations and Financial Condition. On February 5, 2026, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and nine months ended December 31, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter and nine months ended December 31, 2025 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition. On November 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and six months ended September 30, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter and six months ended September 30, 2025 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Entry into a Material Definitive Agreement. On August 4, 2025, Medtech Pharma Holdings Limited (“Purchaser”), an Ontario corporation and a wholly-owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), entered into a definitive agreement (the “Share Purchase Agreement”) with ANJAC SAS, a French company (“ANJAC”). The Share Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire all of the shares of Pillar…

Results of Operations and Financial Condition. On August 7, 2025, the Company announced financial results for the fiscal quarter ended June 30, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter ended June 30, 2025 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition. On May 8, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and year ended March 31, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2025 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition. On February 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and nine months ended December 31, 2024. A copy of the press release announcing the Company's earnings results for the fiscal quarter and nine months ended December 31, 2024 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

CFO — Christine Sacco: The CFO was appointed to an additional role as COO, representing an expansion of responsibilities rather than a departure.

Results of Operations and Financial Condition. On November 7, 2024, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and six months ended September 30, 2024. A copy of the press release announcing the Company's earnings results for the fiscal quarter and six months ended September 30, 2024 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Results of Operations and Financial Condition. On August 8, 2024, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter ended June 30, 2024. A copy of the press release announcing the Company's earnings results for the fiscal quarter ended June 30, 2024 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Other Events . On May 14, 2024, the Company also announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300.0 million of the Company's issued and outstanding common stock. The repurchases may occur in open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing, and the timing and amount…

above is incorporated by reference as if fully set forth herein. On May 14, 2024, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and year ended March 31, 2024 using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”). The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection wit…

Director — John F. Kelly: The filing announces the election of a new independent director to the Board of Directors, which is a standard governance event and not a departure of a senior executive.